These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21149474)

  • 1. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.
    de Langen AJ; van den Boogaart V; Lubberink M; Backes WH; Marcus JT; van Tinteren H; Pruim J; Brans B; Leffers P; Dingemans AM; Smit EF; Groen HJ; Hoekstra OS
    J Nucl Med; 2011 Jan; 52(1):48-55. PubMed ID: 21149474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers.
    Liu BJ; Dong JC; Xu CQ; Zuo CT; Le JJ; Guan YH; Zhao J; Wu JF; Duan XH; Cao YX
    Chin Med J (Engl); 2009 Aug; 122(15):1749-54. PubMed ID: 19781319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT.
    Kasai T; Motoori K; Horikoshi T; Uchiyama K; Yasufuku K; Takiguchi Y; Takahashi F; Kuniyasu Y; Ito H
    Eur J Radiol; 2010 Aug; 75(2):143-6. PubMed ID: 19446975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging to optimally stage lung cancer: conventional modalities and PET/CT.
    Truong MT; Munden RF; Movsas B
    J Am Coll Radiol; 2004 Dec; 1(12):957-64. PubMed ID: 17411738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer.
    Gourin CG; Watts TL; Williams HT; Patel VS; Bilodeau PA; Coleman TA
    Laryngoscope; 2008 Apr; 118(4):671-5. PubMed ID: 18197136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
    Lardinois D; Weder W; Hany TF; Kamel EM; Korom S; Seifert B; von Schulthess GK; Steinert HC
    N Engl J Med; 2003 Jun; 348(25):2500-7. PubMed ID: 12815135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
    Hahn S; Heusner T; Zhou X; Zhan Y; Peng Z; Hamami M; Forsting M; Bockisch A; Antoch G
    Rofo; 2010 Mar; 182(3):243-7. PubMed ID: 19859858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.
    Nomori H; Mori T; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
    J Thorac Cardiovasc Surg; 2008 Apr; 135(4):816-22. PubMed ID: 18374761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT and PET imaging in non-small cell lung cancer.
    Knoepp UW; Ravenel JG
    Crit Rev Oncol Hematol; 2006 Apr; 58(1):15-30. PubMed ID: 16386435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
    van den Boogaart VE; de Lussanet QG; Houben RM; de Ruysscher D; Groen HJ; Marcus JT; Smit EF; Dingemans AM; Backes WH
    Lung Cancer; 2016 Mar; 93():20-7. PubMed ID: 26898610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.